| Basics |
Adverum Biotechnologies, Inc.
Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.
|
| IPO Date: |
May 12, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$57.03M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 3.60%
|
| Avg Daily Range (30 D): |
$0.22 | 5.52%
|
| Avg Daily Range (90 D): |
$0.18 | 4.28%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.74M |
| Avg Daily Volume (30 D): |
.27M |
| Avg Daily Volume (90 D): |
.19M |
| Trade Size |
| Avg Trade Size (Sh.): |
177 |
| Avg Trade Size (Sh.) (30 D): |
127 |
| Avg Trade Size (Sh.) (90 D): |
102 |
| Institutional Trades |
| Total Inst.Trades: |
1,058 |
| Avg Inst. Trade: |
$1.82M |
| Avg Inst. Trade (30 D): |
$1.48M |
| Avg Inst. Trade (90 D): |
$1.28M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.18M |
| Avg Closing Trade (30 D): |
$.65M |
| Avg Closing Trade (90 D): |
$.65M |
| Avg Closing Volume: |
29.67K |
|
|
|
|
| Financials |
| |
TTM |
Q2 2024 |
Q1 2024 |
|
Basic EPS
|
$-1.3
|
$-.89
|
$-1.5
|
|
Diluted EPS
|
$-1.3
|
$-.89
|
$-1.5
|
|
Revenue
|
$ 1M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -27.13M
|
$ -18.48M
|
$ -24.79M
|
|
Operating Income / Loss
|
$ -29.22M
|
$ -20.88M
|
$ -26.84M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -34.47M
|
$ -22.29M
|
$ 74.61M
|
|
PE Ratio
|
|
|
|
| Splits |
| Mar 21, 2024:
10:1
|
|
